CO5580754A2 - Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina - Google Patents

Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina

Info

Publication number
CO5580754A2
CO5580754A2 CO05062906A CO05062906A CO5580754A2 CO 5580754 A2 CO5580754 A2 CO 5580754A2 CO 05062906 A CO05062906 A CO 05062906A CO 05062906 A CO05062906 A CO 05062906A CO 5580754 A2 CO5580754 A2 CO 5580754A2
Authority
CO
Colombia
Prior art keywords
beta
inhibitor
rotonina
reabsortion
norepinefrine
Prior art date
Application number
CO05062906A
Other languages
English (en)
Inventor
Wienrich Marion
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5580754A2 publication Critical patent/CO5580754A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

1.- Composición que comprende: (a) una cantidad farmacéuticamente eficaz de uno o varios inhibidores de la reabsorción de serotonina y/o norepinefrina, eventualmente en forma de una sal farmacéuticamente eficaz de los mismos, preferiblemente de un inhibidor combinado de la reabsorción de serotonina y de norepinefrina, y (b) una cantidad farmacéuticamente eficaz de uno o varios agonistas de receptor adrenérgico beta-3, eventualmente en forma de una sal farmacéuticamente eficaz de los mismos.2.- Composición según la reivindicación 1, en la cual el al menos un componente (a) está seleccionado del grupo compuesto por tandamina, pirandamina, ciclazindol, fluparoxan, lortalamina, talsupram, talopram, prindamina, nomifensina, viloxazina, tomoxetina, duloxetina, venlafaxina, milnacipran y reboxetina, y mezclas de los mismos.3.- Composición según una de las reivindicaciones 1 ó 2, en la cual el componente (b) es (-)-2-[4-(2-{[(1S,2R)-2-hidroxi-2-(4-hidroxifenil)-1-metiletil]-amino}-etil)-2,5-dimetilfeniloxi]acetato de etilo y/o ácido (-)-2-[4-(2- {[(1S,2R)-2-hidroxi-2-(4-hidroxifenil)-1-metiletil]amino}etil)-2,5-dimetilfeniloxi]acético y/o una sal farmacológicamente aceptable de los mismos, y/o un enantiómero de los mismos.4.- Composición según una de las reivindicaciones 1 a 3, en la cual el componente (a) es duloxetina y se encuentra, o bien en su forma racémica o bien en su forma enantiómera (+), y el componente (b) es (-)-2-[4-(2-{[(1S,2R)-2-hidroxi-2-(4-hidroxifenil)-1-metiletil]amino}etil)-2,5-dimetilfeniloxi]acetato de etilo y/o ácido (-)-2-[4-(2-{[(1S, 2R)-2-hidroxi-2-(4-hidroxifenil)-1-metiletil]amino}etil)-2,5-dimetilfeniloxi]acético y/o una sal farmacéuticamente aceptable de los mismos.5.- Composición según la reivindicación 4, que contiene aproximadamente 0,1 mg a aproximadamente 500 mg de duloxetina y aproximadamente 10 mg a aproximadamente 750 mg de componente (b).6.- Composición según cualquiera de las reivindicaciones 1 a 5, en la cual el componente (a) y el componente (b) están formulados en la misma forma de administración.
CO05062906A 2002-11-27 2005-06-27 Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina CO5580754A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026546A EP1424079A1 (en) 2002-11-27 2002-11-27 Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine

Publications (1)

Publication Number Publication Date
CO5580754A2 true CO5580754A2 (es) 2005-11-30

Family

ID=32241298

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05062906A CO5580754A2 (es) 2002-11-27 2005-06-27 Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina

Country Status (22)

Country Link
US (2) US20050261328A1 (es)
EP (4) EP1424079A1 (es)
JP (2) JP2006509751A (es)
KR (1) KR20050088295A (es)
CN (1) CN1717230A (es)
AT (1) ATE399005T1 (es)
AU (2) AU2003285312A1 (es)
BR (1) BR0316535A (es)
CA (2) CA2507266A1 (es)
CO (1) CO5580754A2 (es)
DE (1) DE50310046D1 (es)
EA (1) EA009781B1 (es)
EC (1) ECSP055814A (es)
ES (1) ES2309371T3 (es)
HR (1) HRP20050467A2 (es)
MX (1) MXPA05005483A (es)
NO (1) NO20053088L (es)
PL (1) PL376259A1 (es)
RS (1) RS20050392A (es)
UA (1) UA81931C2 (es)
WO (2) WO2004047830A2 (es)
ZA (1) ZA200503282B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
RU2006119331A (ru) * 2003-11-03 2007-12-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА, α-АНТАГОНИСТ И/ИЛИ ИНГИБИТОР 5α-РЕДУКТАЗЫ
DE10356112A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
EP1804778A1 (de) * 2004-10-18 2007-07-11 Boehringer Ingelheim International GmbH Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
US20090247781A1 (en) * 2004-10-26 2009-10-01 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
US9440003B2 (en) * 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
JP5124286B2 (ja) * 2006-01-10 2013-01-23 キッセイ薬品工業株式会社 徐放性製剤およびその製造方法
EP1919467A2 (en) * 2006-05-22 2008-05-14 Teva Pharmaceutical Industries Ltd Duloxetine hydrochloride delayed release formulations
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
EP2216021B1 (en) 2007-11-02 2012-10-17 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010037849A1 (en) * 2008-10-02 2010-04-08 Laboratorios Del Dr. Esteve, S.A. Duloxetine enteric pellets
EP2363397A4 (en) * 2008-11-07 2012-07-11 Dainippon Sumitomo Pharma Co NEW THERAPEUTIC AGENT USEFUL FOR SYMPTOM OF LOWER URINARY TRACT
EP2316432A1 (de) * 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2377525A1 (en) * 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
AU2011285928B9 (en) * 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
WO2013119910A1 (en) * 2012-02-09 2013-08-15 Altherx, Inc. Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
MX2015003110A (es) * 2012-09-18 2015-06-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP3362140A1 (en) 2015-10-15 2018-08-22 Duke University State-dependent peripheral neuromodulation to treat bladder dysfunction
IL258856B1 (en) 2015-10-23 2024-03-01 Velicept Therapeutics Inc Zwitterion solvegron and its uses
WO2017186593A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Tablets comprising mirabegron and solifenacin
EP3448366A1 (en) 2016-04-25 2019-03-06 Synthon B.V. Modified release tablet composition comprising mirabegron
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA2061665C (en) * 1991-02-25 2002-04-16 Mark Mortensen Foreman Treatment of lower urinary tract disorders
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
HUP9802318A3 (en) * 1995-10-26 2001-04-28 Mitsubishi Tokyo Pharm Inc Phenylethanolamine derivatives, process for producing the same, and intermediates in the production of the same
ES2208772T3 (es) * 1996-01-10 2004-06-16 Asahi Kasei Kabushiki Kaisha Nuevos compuestos triciclicos y compuestos farmaceuticos que contienen los mismos.
EP0888330B1 (en) * 1996-03-11 2003-05-07 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
KR20000068208A (ko) * 1996-08-19 2000-11-25 간자와 무츠와 빈뇨 및 요실금의 예방·치료제
CN1237160A (zh) * 1996-11-14 1999-12-01 辉瑞大药厂 取代的吡啶的制备方法
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
JPH1112171A (ja) * 1997-06-19 1999-01-19 Nisshin Flour Milling Co Ltd 消化器疾患治療薬
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
EP1028111B1 (en) * 1997-10-17 2004-05-12 Yamanouchi Pharmaceutical Co. Ltd. Amide derivatives or salts thereof
PL341221A1 (en) * 1997-12-18 2001-03-26 Kissei Pharmaceutical Derivatives of phenylaminoalkyl carboxylic acid and pharmacological compositions containing them
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
US6495546B1 (en) * 1998-04-06 2002-12-17 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
CA2328348C (en) * 1998-04-14 2009-03-03 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
EP2153825A1 (en) * 1998-08-27 2010-02-17 Pfizer Health AB Therapeutic formulation for administering tolterodine with controlled release
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
SI1227806T1 (sl) * 1999-11-11 2005-12-31 Pfizer Health Ab Farmacevtska formulacija, ki vsebuje tolterodin in njena uporaba
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
JP2003523382A (ja) * 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
AU5596600A (en) * 2000-06-07 2001-12-17 Bridge Pharma Inc Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
US6696450B2 (en) * 2001-04-04 2004-02-24 Wyeth Serotonergic agents with long-acting in vivo effects
WO2003035600A1 (fr) * 2001-10-19 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Procede de production de derive de benzocycloheptene
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
MXPA04008037A (es) * 2002-02-19 2004-11-26 Pharmacia Corp Uso de inhibidores de la ciclooxigenasa y de agentes antimuscarinicos para el tratamiento de la incontinencia.

Also Published As

Publication number Publication date
ATE399005T1 (de) 2008-07-15
US20050261369A1 (en) 2005-11-24
EA009781B1 (ru) 2008-04-28
AU2003289854A1 (en) 2004-06-18
CA2507343A1 (en) 2005-07-14
CA2507266A1 (en) 2004-06-10
BR0316535A (pt) 2005-10-04
NO20053088L (no) 2005-06-23
ES2309371T3 (es) 2008-12-16
WO2004047838A3 (de) 2004-10-28
MXPA05005483A (es) 2005-08-16
EP1640000A3 (de) 2007-01-17
ZA200503282B (en) 2006-07-26
EP1567149A2 (de) 2005-08-31
EA200500776A1 (ru) 2005-12-29
ECSP055814A (es) 2005-08-11
WO2004047838A2 (de) 2004-06-10
RS20050392A (en) 2007-04-10
WO2004047830A3 (de) 2004-08-19
CN1717230A (zh) 2006-01-04
UA81931C2 (uk) 2008-02-25
US20090012161A9 (en) 2009-01-08
AU2003285312A1 (en) 2004-06-18
US20050261328A1 (en) 2005-11-24
EP1424079A1 (en) 2004-06-02
EP1572181A2 (de) 2005-09-14
WO2004047830A2 (de) 2004-06-10
JP2006509752A (ja) 2006-03-23
DE50310046D1 (de) 2008-08-07
EP1640000A2 (de) 2006-03-29
PL376259A1 (en) 2005-12-27
EP1572181B1 (de) 2008-06-25
KR20050088295A (ko) 2005-09-05
HRP20050467A2 (en) 2006-06-30
JP2006509751A (ja) 2006-03-23

Similar Documents

Publication Publication Date Title
CO5580754A2 (es) Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina
MY134110A (en) Combinations of reboxetine and neuroleptic agents
GEP20084325B (en) Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
BR0116206A (pt) Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
EP1631274A4 (en) COMBINATION OF A NMDA RECEPTOR ANTAGONIST AND A SELECTIVE SEROTONINE RECOURSE HEMMER FOR TREATING DEPRESSIONS AND OTHER MUTUAL DISORDERS
NZ589951A (en) 5HT2C receptor modulator compositions and methods of use
WO2001026623A3 (en) Treatment of fatigue, head injury and stroke
MY133238A (en) Monoamine reuptake inhibitors for treatment for cns disorders
DE60320865D1 (de) Zusammensetzung enthaltend einen Tachykininrezeptor Antagonisten und einen Serotonin-Wiederaufnahmehemmer
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
CO6260011A2 (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico
WO2004100939B1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
WO2008037045A3 (en) Composition containing a mixture of antidepressants for treating premature ejaculation.
MX2009004113A (es) Composicion que comprende un antagonista del receptor de neuroquinina-1 y un inhibidor selectivo de la recaptacion de serotonina para el tratamiento de tinnitus y perdida auditiva.
RS51669B (en) NEW DRUG COMBINATIONS AS ANTIDEPRESSIVE
BRPI0412268A (pt) compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a
EP1260221A3 (en) Combination treatment for depression and anxiety
RU2009101143A (ru) Лечение психологических состояний с применением антаггонистов m1-мускариновых рецепторов
MX2007006045A (es) Combinacion farmaceutica que comprende inhibidor selectivo de reabsorcion de serotonina y antagonista del receptor de glucocorticoide para tratamiento de depresion.
ECSP034599A (es) Tratamiento de trastornos de ansiedad
EA200600534A1 (ru) Сочетание ингибитора обратного захвата серотонина и амоксапина
EA200600183A1 (ru) Сочетание ингибитора обратного захвата серотонина и агомелатина
BRPI0413749A (pt) uso de amoxapina ou de um sal farmaceuticamente aceitável, composição farmacêutica, e, kit

Legal Events

Date Code Title Description
FC Application refused